Characteristics of the 80 newly diagnosed patients with cHL
| Characteristic . | Patients, n (%) . |
|---|---|
| Male sex | 42 (52.4) |
| Median age, y | 44 (17-82) |
| Age range, y | 17-82 |
| 17-24 | 19 (23.75) |
| 25-44 | 22 (27.5) |
| 45-60 | 20 (25) |
| 61-82 | 19 (23.75) |
| Histology | |
| Nodular sclerosis | 64 (80) |
| Mixed cellularity | 12 (15.0) |
| Lymphocyte rich | 3 (3.7) |
| Unclassifiable | 1 (1.2) |
| EBER | |
| Positive | 15 (18.7) |
| Negative | 38 (47.5) |
| Not assessable | 27 (33.7) |
| Ann Arbor Stage | |
| I | 2 (2.5) |
| II | 26 (32.5) |
| III | 18 (22.5) |
| IV | 34 (42.5) |
| Stage strata* | |
| Limited | 14 (17.5) |
| Advanced | 66 (82.5) |
| GHSG risk group | |
| Favorable | 3 (3.8) |
| Intermediate | 17 (21.3) |
| Unfavorable | 60 (75.0) |
| IPS | |
| Low, 0-3 | 63 (78.7) |
| High, ≥4 | 17 (21.3) |
| Bulky disease | 16 (20.0) |
| B symptoms | 43 (53.8) |
| Characteristic . | Patients, n (%) . |
|---|---|
| Male sex | 42 (52.4) |
| Median age, y | 44 (17-82) |
| Age range, y | 17-82 |
| 17-24 | 19 (23.75) |
| 25-44 | 22 (27.5) |
| 45-60 | 20 (25) |
| 61-82 | 19 (23.75) |
| Histology | |
| Nodular sclerosis | 64 (80) |
| Mixed cellularity | 12 (15.0) |
| Lymphocyte rich | 3 (3.7) |
| Unclassifiable | 1 (1.2) |
| EBER | |
| Positive | 15 (18.7) |
| Negative | 38 (47.5) |
| Not assessable | 27 (33.7) |
| Ann Arbor Stage | |
| I | 2 (2.5) |
| II | 26 (32.5) |
| III | 18 (22.5) |
| IV | 34 (42.5) |
| Stage strata* | |
| Limited | 14 (17.5) |
| Advanced | 66 (82.5) |
| GHSG risk group | |
| Favorable | 3 (3.8) |
| Intermediate | 17 (21.3) |
| Unfavorable | 60 (75.0) |
| IPS | |
| Low, 0-3 | 63 (78.7) |
| High, ≥4 | 17 (21.3) |
| Bulky disease | 16 (20.0) |
| B symptoms | 43 (53.8) |
GHSG, German Hodgkin Study Group Score; IPS, International Prognostic Score.
Limited stage: IA, IB, or IIA without bulky disease. Advanced stage: III, IV, or I or II with bulky disease or IIB.